Leukemia Stem Cell Detection in Acute Myeloid Leukemia

Status Terminated

Clinical Trial Summary

Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) following induction chemotherapy. However, a large majority subsequently relapse and succumb to the disease. Currently, cytogenetics and molecular aberrations are the best prognostic indicators; however, these factors cannot prognosticate accurately for individual patients. Overall, the majority of patients with favorable or intermediate-risk AML will experience relapse. Prognosis after relapse is dismal with a five-year overall survival rate of less than 10%. A leukemia stem cell (LSC) paradigm may explain this failure of CR to reliably translate into cure. This study is undertaken to determine whether the presence of LSCs has prognostic value as well as to determine whether the presence of LSCs has predictive value. This study has an observational component, whereby we intent evaluate whether the presence or absence of LSCs is prognostic. This study also has an interventional component in which it uses LSC status to determine whether favorable and intermediate risk AML patients in CR receive consolidation with chemotherapy or allogeneic HCT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02927938
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact
Status	Terminated
Phase	Phase 3
Start date	September 2016
Completion date	October 5, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04240002` - A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)	Phase 1/Phase 2
Completed	`NCT02626715` - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS	Phase 2
Completed	`NCT05488613` - Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Completed	`NCT02265731` - Study Evaluating Venetoclax in Subjects With Hematological Malignancies	Phase 1/Phase 2
Completed	`NCT01772953` - Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT	Phase 2
Recruiting	`NCT03188874` - Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Completed	`NCT00071006` - AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)	Phase 2
Completed	`NCT04079296` - A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)	Phase 1/Phase 2
Completed	`NCT04509622` - A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)	Phase 3
Withdrawn	`NCT03699384` - Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)	Phase 1/Phase 2
Recruiting	`NCT03613532` - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Phase 1
Completed	`NCT02252107` - 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1	Phase 2
Terminated	`NCT02259348` - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation	Phase 2
Terminated	`NCT01463410` - Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler	N/A
Completed	`NCT01242774` - Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)	Phase 1
Terminated	`NCT02134782` - Yoga Fatigue Study	N/A
Completed	`NCT01685619` - AML-MDS Novel Prognostic Tests Clinical Study
Completed	`NCT03625505` - A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia	Phase 1
Active, not recruiting	`NCT04266795` - A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy	Phase 2
Recruiting	`NCT04446741` - Molecular Diagnostic Platform for AML